These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 29559421)

  • 1. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
    J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
    Katzenstein TL; Faurholt-Jepsen D; Qvist T; Jensen PØ; Pressler T; Johansen HK; Kolpen M
    APMIS; 2023 Aug; 131(8):419-425. PubMed ID: 37294911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Gherardi G; Linardos G; Pompilio A; Fiscarelli E; Di Bonaventura G
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):297-303. PubMed ID: 30803726
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Caverly LJ; Spilker T; Kalikin LM; Stillwell T; Young C; Huang DB; LiPuma JJ
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
    Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
    J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018.
    Jean SS; Lee YL; Liu PY; Lu MC; Ko WC; Hsueh PR
    J Microbiol Immunol Infect; 2022 Jun; 55(3):463-473. PubMed ID: 34503920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V; Grohs P; Compain F
    J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon.
    Araj GF; Berjawi DM; Musharrafieh U; El Beayni NK
    J Infect Dev Ctries; 2020 Jun; 14(6):559-564. PubMed ID: 32683345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
    Shortridge D; Streit J; Pfaller M; Tulloch M; Chen WT; Castanheira M
    J Glob Antimicrob Resist; 2022 Dec; 31():98-103. PubMed ID: 35988706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
    Sader HS; Carvalhaes CG; Duncan LR; Flamm RK; Shortridge D
    J Antimicrob Chemother; 2020 Oct; 75(10):2907-2913. PubMed ID: 32653914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.